Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marina Noris

Showing results (11-20 of 184) with videos related to

Pageof 19
Sort By:
Kidney International|October 31, 2020
Atypical hemolytic uremic syndrome associated with a factor B genetic variant and fluid-phase complement activation: an exception to the rule?Marina Noris, Giuseppe Remuzzi
Kidney International|October 20, 2024
Looking into the cholesterol crystal ball: is complement the answer?Marina Noris, Giuseppe Remuzzi
Kidney International|June 24, 2019
Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bit of both?Marina Noris, Giuseppe Remuzzi
Kidney International|December 1, 2010
Klotho in acute kidney injury: biomarker, therapy, or a bit of both?Sistiana Aiello, Marina Noris
Seminars in Nephrology|September 3, 2010
Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpuraMarina Noris, Giuseppe Remuzzi
Nature Clinical Practice. Nephrology|August 26, 2006
Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management?Marina Noris, Giuseppe Remuzzi
Current Opinion in Nephrology and Hypertension|October 1, 2013
Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantationMarina Noris, Giuseppe Remuzzi
Kidney International|March 29, 2002
ACE inhibitors and AT1 receptor antagonists: is two better than one?Marina Noris, Giuseppe Remuzzi
Nature Reviews. Nephrology|January 15, 2014
Cardiovascular complications in atypical haemolytic uraemic syndromeMarina Noris, Giuseppe Remuzzi
Seminars in Nephrology|September 3, 2017
Genetics of Immune-Mediated Glomerular Diseases: Focus on ComplementMarina Noris, Giuseppe Remuzzi
Pageof 19

Showing results (11-20 of 184) with videos related to

Sort By:
Pageof 19
Kidney International|October 31, 2020
Atypical hemolytic uremic syndrome associated with a factor B genetic variant and fluid-phase complement activation: an exception to the rule?Marina Noris, Giuseppe Remuzzi
Kidney International|October 20, 2024
Looking into the cholesterol crystal ball: is complement the answer?Marina Noris, Giuseppe Remuzzi
Kidney International|June 24, 2019
Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bit of both?Marina Noris, Giuseppe Remuzzi
Kidney International|December 1, 2010
Klotho in acute kidney injury: biomarker, therapy, or a bit of both?Sistiana Aiello, Marina Noris
Seminars in Nephrology|September 3, 2010
Genetics and genetic testing in hemolytic uremic syndrome/thrombotic thrombocytopenic purpuraMarina Noris, Giuseppe Remuzzi
Nature Clinical Practice. Nephrology|August 26, 2006
Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management?Marina Noris, Giuseppe Remuzzi
Current Opinion in Nephrology and Hypertension|October 1, 2013
Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantationMarina Noris, Giuseppe Remuzzi
Kidney International|March 29, 2002
ACE inhibitors and AT1 receptor antagonists: is two better than one?Marina Noris, Giuseppe Remuzzi
Nature Reviews. Nephrology|January 15, 2014
Cardiovascular complications in atypical haemolytic uraemic syndromeMarina Noris, Giuseppe Remuzzi
Seminars in Nephrology|September 3, 2017
Genetics of Immune-Mediated Glomerular Diseases: Focus on ComplementMarina Noris, Giuseppe Remuzzi
Pageof 19